143 related articles for article (PubMed ID: 11119918)
21. Successful therapy of chronic renal allograft failure by enhanced immunosuppression.
Kliem V; Tiroke T; Ehlerding G; Eberhard O; Behrend M; Frei U; Koch KM; Pichlmayr R; Brunkhorst R
Transplant Proc; 1998 Jun; 30(4):1207-9. PubMed ID: 9636490
[No Abstract] [Full Text] [Related]
22. Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients.
Birkeland SA
Transplantation; 2001 Apr; 71(8):1089-90. PubMed ID: 11374407
[TBL] [Abstract][Full Text] [Related]
23. Single-center experience of 60 consecutive simultaneous pancreas-kidney transplants using mycophenolate mofetil and tacrolimus as primary maintenance immunotherapy.
Kaufman DB; Leventhal JR; Stuart J; Parker M; Abecassis M; Fryer JP; Stuart FP
Transplant Proc; 1999; 31(1-2):615-6. PubMed ID: 10083261
[No Abstract] [Full Text] [Related]
24. Comparison of the safety and efficacy of mycophenolate mofetil, prednisolone and cyclosporine and conventional cyclosporine and prednisolone in kidney transplantation.
Kim HC; Park SB; Kim HT; Cho WH; Park CH
Transplant Proc; 2000 Nov; 32(7):1751-2. PubMed ID: 11119919
[No Abstract] [Full Text] [Related]
25. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
[No Abstract] [Full Text] [Related]
26. Influence of immunosuppressive therapy on infectious complications in renal transplant recipients.
Klauser R; Zlabinger GJ; Traindl O; Franz M; Watschinger B; Pohanka E; Kudlacek S; Kovarik J
Transplant Proc; 1992 Feb; 24(1):292-4. PubMed ID: 1539284
[No Abstract] [Full Text] [Related]
27. FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group.
Miller J; Pirsch JD; Deierhoi M; Vincenti F; Filo RS
Transplant Proc; 1997; 29(1-2):304-5. PubMed ID: 9123008
[No Abstract] [Full Text] [Related]
28. Mycofenolate mofetil-cyclosporine immunosuppression of kidney transplantation recipients with two different corticosteroid doses.
Remport A; Sasvári I; Toronyi E; Borka P; Lázár N; Járay J; Perner F
Transplant Proc; 2001 May; 33(3):2302-3. PubMed ID: 11377537
[No Abstract] [Full Text] [Related]
29. Mycophenolate mofetil/prednisolone/single-shot ATG with tacrolimus or cyclosporine in pancreas/kidney transplantation: first results of an ongoing prospective randomized trial.
Schulz T; Konzack J; Büsing M
Transplant Proc; 1999; 31(1-2):591-2. PubMed ID: 10083251
[No Abstract] [Full Text] [Related]
30. The role of immunosuppressive drugs in transplantation.
Triemer H
J Med Assoc Ga; 1998 Apr; 87(2):93-6. PubMed ID: 16259250
[No Abstract] [Full Text] [Related]
31. Tacrolimus/mycophenolate mofetil/steroid-based immunosuppression after pancreas-kidney transplantation with single shot antithymocyte globulin.
Schulz T; Martin D; Heimes M; Klempnauer J; Buesing M
Transplant Proc; 1998 Jun; 30(4):1533-5. PubMed ID: 9636623
[No Abstract] [Full Text] [Related]
32. Lymphocyte subsets in renal transplant recipients treated with mycophenolate mofetil.
François M; Büchler M; Halimi JM; Al-Najjar A; Valentin JF; Thibault G; Lebranchu Y
Transplant Proc; 2000 Dec; 32(8):2781-2. PubMed ID: 11134803
[No Abstract] [Full Text] [Related]
33. Beneficial effects of low-toxicity regimens with MMF in renal recipients with late allograft dysfunction.
Folkmane I; Bernarde K; Bicans J; Amerika D; Rozentals R
Transplant Proc; 2003 Mar; 35(2):789-90. PubMed ID: 12644138
[No Abstract] [Full Text] [Related]
34. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation.
Ettenger R; Cohen A; Nast C; Moulton L; Marik J; Gales B
Transplant Proc; 1997; 29(1-2):340-1. PubMed ID: 9123030
[No Abstract] [Full Text] [Related]
35. Omission of azathioprine and mycophenolate mofetil in immunosuppressive regimen in kidney transplantation.
Taheri M; Pourmand G; Mehrsai AR; Mansoori D
Transplant Proc; 2003 Nov; 35(7):2752-3. PubMed ID: 14612105
[No Abstract] [Full Text] [Related]
36. Mycophenolate mofetil, ATG, and cyclosporine in the induction treatment of renal transplant recipients minimizes the incidence of acute rejection episodes.
Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Marcas LI; Manresa JM; Masramón J
Transplant Proc; 1998 Aug; 30(5):2226-7. PubMed ID: 9723449
[No Abstract] [Full Text] [Related]
37. Treatment of chronic rejection in renal transplantation by mycophenolate mofetil (MMF): a preliminary report of six-month experience.
Jirasiritham S; Sumethkul V; Mavichak V; Jirasiritham S; Chiewsilp P; Leenanupunth C; Kochakarn W
Transplant Proc; 1998 Nov; 30(7):3576-7. PubMed ID: 9838566
[No Abstract] [Full Text] [Related]
38. Effect of glucocorticoid-free immunosuppressive protocol on serum lipids in renal transplant patients.
Nowacka-Cieciura E; Soluch L; Cieciura T; Lewandowska D; Durlik M; Shaibani B; Serafinowicz A; Szmidt J; Rowiński W; Lao M
Transplant Proc; 2000 Sep; 32(6):1339-43. PubMed ID: 10995973
[No Abstract] [Full Text] [Related]
39. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
40. The effect of different immunosuppression on the outcome of pediatric renal transplants.
García Meseguer C; Alonso A; Vanegas JJ; Martinez Débora MJ; Navarro M
Transplant Proc; 1999 Sep; 31(6):2280. PubMed ID: 10500577
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
